Bonni Goldstein, MD - CannMed 2024 - Innovation & Investment Summit

Bonni Goldstein, MD
Medical Director / Owner
Canna-Centers Wellness
ADVISORY BOARD MEMBER
SPEAKER
MEDICINE

Applying Machine Learning Tools to the ASD Cannabis‑Responsive™ Biomarker Database: Paving the way

Cannabis‑responsive™ (C-Res™) biomarkers are metabolites found in saliva of patients that change in response to medical cannabis (MC) treatment. This objective technology characterizes treatment as successful when C-Res™ values shift to the physiological range determined by typically-developing control groups, and is especially relevant for medical conditions where evaluation of treatment currently relies on subjective evaluation. In a proof-of-concept study, we have demonstrated that the levels of C-Res™ biomarkers found in children with autism spectrum disorder (ASD) shift towards the physiological levels detected in typically developing (TD) children in response to successful physician-directed MC treatment (Siani-Rose et al, 2021 and 2022).

Learning Objectives:

Identify biomarkers distinguishing ASD and TD groups
Show the phytochemical entourage effect
Demonstrate that THC and CBD are associated with two distinct groups of C-Res™ biomarkers, while CBG is associated with some biomarkers from both groups

BIO

Bonni Goldstein, MD is the Medical Director of Canna-Centers Wellness & Education, a medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions. She completed her internship and residency at Children’s Hospital Los Angeles, where she also served as chief resident. After years of working in the specialty of Pediatric Emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.

Over the last 15 years she has evaluated thousands of patients for use of medical cannabis and is recognized as an expert in the clinical application of cannabis therapeutics. She has a special interest in treating children with intractable epilepsy, autism, cancer and other conditions. Dr. Goldstein’s latest book, “Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain” was published in September 2020 by Little, Brown Spark. Dr. Goldstein recently co-authored two peer-reviewed articles researching the use of Cannabis- Responsive biomarkers to document cannabis treatment efficacy, guide clinical decision-making and improve outcomes in children with autism.

Dr Goldstein is a board member for the International Association for Cannabinoid Medicine, a board member of Autism Safe Haven and is Medical Advisor to Cannformatics as well as Medical Advisor to Weedmaps.